| Aggregate Evidence Quality . | Grade B . |
|---|---|
| Benefits | ACE inhibitor and ARB therapy has been shown in the short-term to be effective in reducing urine proteinuria |
| Risks, harm, cost | Positive effect on urine protein concentrations after the receipt of an ACE inhibitor may not be sustained over time |
| Benefit–harm assessment | Treatment with an ACE inhibitor or ARB may lower the rate of progression of renal disease even if the effect is not sustained in the long-term |
| Intentional vagueness | Whether to aggressively treat the BP so that it is <90th percentile |
| Role of patient preferences | Patients may have concerns about the choice of medication, which should be addressed |
| Exclusions | Children without CKD |
| Strength | Strong recommendation |
| Key references | 173,464,465,485,487,488 |
| Aggregate Evidence Quality . | Grade B . |
|---|---|
| Benefits | ACE inhibitor and ARB therapy has been shown in the short-term to be effective in reducing urine proteinuria |
| Risks, harm, cost | Positive effect on urine protein concentrations after the receipt of an ACE inhibitor may not be sustained over time |
| Benefit–harm assessment | Treatment with an ACE inhibitor or ARB may lower the rate of progression of renal disease even if the effect is not sustained in the long-term |
| Intentional vagueness | Whether to aggressively treat the BP so that it is <90th percentile |
| Role of patient preferences | Patients may have concerns about the choice of medication, which should be addressed |
| Exclusions | Children without CKD |
| Strength | Strong recommendation |
| Key references | 173,464,465,485,487,488 |